Search research articles
Contact Us
Filters
Showing results (1-10 of 8) with videos related to
Page
of 1
Sort By:
Developmental Cognitive Neuroscience
|
August 4, 2022
The HAPPE plus Event-Related (HAPPE+ER) software: A standardized preprocessing pipeline for event-related potential analyses
A D Monachino, K L Lopez, L J Pierce, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
|
July 1, 1995
Association and colocalization of K+ channel alpha- and beta-subunit polypeptides in rat brain
K J Rhodes, S A Keilbaugh, N X Barrezueta, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
March 13, 2008
A phase II, multicenter trial of weekly topotecan in patients with recurrent platinum-sensitive epithelial cancers of the ovary and peritoneum
J V Brown, M A Rettenmaier, K L Lopez, et al.
Neuroimage
|
May 11, 2023
Stability, change, and reliable individual differences in electroencephalography measures: A lifespan perspective on progress and opportunities
K L Lopez, A D Monachino, K M Vincent, et al.
Neuroimage
|
July 11, 2022
HAPPILEE: HAPPE In Low Electrode Electroencephalography, a standardized pre-processing software for lower density recordings
K L Lopez, A D Monachino, S Morales, et al.
European Journal of Gynaecological Oncology
|
November 17, 2010
Bevacizumab, paclitaxel and carboplatin for advanced ovarian cancer: low risk of gastrointestinal and cardiovascular toxicity
L N Abaid, K L Lopez, J P Micha, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))
|
March 16, 2013
Pegfilgrastim safely administered on the same day as dose-dense chemotherapy for patients with advanced-stage ovarian carcinoma
J P Micha, J V Brown, M A Rettenmaier, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
March 9, 2007
A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer
J P Micha, B H Goldstein, M A Rettenmaier, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 8) with videos related to
Sort By:
Page
of 1
Developmental Cognitive Neuroscience
|
August 4, 2022
The HAPPE plus Event-Related (HAPPE+ER) software: A standardized preprocessing pipeline for event-related potential analyses
A D Monachino, K L Lopez, L J Pierce, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
|
July 1, 1995
Association and colocalization of K+ channel alpha- and beta-subunit polypeptides in rat brain
K J Rhodes, S A Keilbaugh, N X Barrezueta, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
March 13, 2008
A phase II, multicenter trial of weekly topotecan in patients with recurrent platinum-sensitive epithelial cancers of the ovary and peritoneum
J V Brown, M A Rettenmaier, K L Lopez, et al.
Neuroimage
|
May 11, 2023
Stability, change, and reliable individual differences in electroencephalography measures: A lifespan perspective on progress and opportunities
K L Lopez, A D Monachino, K M Vincent, et al.
Neuroimage
|
July 11, 2022
HAPPILEE: HAPPE In Low Electrode Electroencephalography, a standardized pre-processing software for lower density recordings
K L Lopez, A D Monachino, S Morales, et al.
European Journal of Gynaecological Oncology
|
November 17, 2010
Bevacizumab, paclitaxel and carboplatin for advanced ovarian cancer: low risk of gastrointestinal and cardiovascular toxicity
L N Abaid, K L Lopez, J P Micha, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))
|
March 16, 2013
Pegfilgrastim safely administered on the same day as dose-dense chemotherapy for patients with advanced-stage ovarian carcinoma
J P Micha, J V Brown, M A Rettenmaier, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
March 9, 2007
A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer
J P Micha, B H Goldstein, M A Rettenmaier, et al.
Page
of 1